Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• BNZ at a 353-fold higher dose (100 mg/kg/day over 20 days: 2000 mg/kg TD [52]). The study of the effect of pH-sensitive liposomes for etanidazole delivery to CD models was discontinued, but along with BNZ-polymersomes both showed that ultralow doses of the antiparasitic drug could reduce infection and

Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review

• Douglas Dourado,
• Thayse Silva Medeiros,
• Éverton do Nascimento Alencar,
• Edijane Matos Sales and
• Fábio Rocha Formiga

Beilstein J. Nanotechnol. 2024, 15, 37–50, doi:10.3762/bjnano.15.4

• nanocarriers intended for the treatment of leishmaniasis. Keywords: antiparasitic; Curcuma longa; curcuminoids; leishmaniasis; nanocarriers; neglected tropical diseases; Introduction Neglected tropical diseases (NTDs) comprise a group of 20 diseases that are caused, in most cases, by viruses, fungi, bacteria

• disease continues to be of utmost importance [9]. Current studies have highlighted curcumin as a promising antiparasitic alternative [10]. Curcumin (diferuloylmethane) is a yellow polyphenol extracted from the rhizome of Curcuma longa, popularly known as turmeric [11][12][13]. This molecule presents a

• curc has great potential for the treatment of various diseases in humans [37][38][39]. Among the diverse biological potential of this molecule, its antiparasitic properties against different diseases have attracted considerable attention in recent decades [10][40][41]. Among such, the potential of curc

Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies

• Giuliana Muraca,
• María Esperanza Ruiz,
• Rocío C. Gambaro,
• Sebastián Scioli-Montoto,
• María Laura Sbaraglini,
• Gisel Padula,
• José Sebastián Cisneros,
• Cecilia Yamil Chain,
• Vera A. Álvarez,
• Cristián Huck-Iriart,
• Guillermo R. Castro,
• María Belén Piñero,
• Matias Ildebrando Marchetto,
• Catalina Alba Soto,
• Germán A. Islan and
• Alan Talevi

Beilstein J. Nanotechnol. 2023, 14, 804–818, doi:10.3762/bjnano.14.66

• blood samples as was described for other type of nanoparticles [45]. Our results suggest that the reported NLC-BNZ formulations are hemocompatible [43]. In vitro antiparasitic activity As shown in Figure 12A, free BNZ displayed a clear dose-dependent effect on T. cruzi trypomastigotes (with an EC50 of

Antibacterial activity of a berberine nanoformulation

• Hue Thi Nguyen,
• Tuyet Nhung Pham,
• Anh-Tuan Le,
• Nguyen Thanh Thuy,
• Tran Quang Huy and
• Thuy Thi Thu Nguyen

Beilstein J. Nanotechnol. 2022, 13, 641–652, doi:10.3762/bjnano.13.56

• Canadensis [2]. Many studies have shown the pharmacological actions of BBR including antimicrobial [3][4], antiviral [5][6], anti-inflammatory [7] and antiparasitic effects [8], and effects against hyperlipidemia [9], hypoglycemia [10] and cancer [11]. BBR has the ability to inhibit or kill many pathogenic

Multilayer capsules made of weak polyelectrolytes: a review on the preparation, functionalization and applications in drug delivery

• Varsha Sharma and
• Anandhakumar Sundaramurthy

Beilstein J. Nanotechnol. 2020, 11, 508–532, doi:10.3762/bjnano.11.41

• from Staphylococcus aureus) was adsorbed on PGA/PLL film via electrostatic attraction and the in vitro cell contact with this protein mainly occurred via local film degradation [103]. The antitumoral, antitoxic, anticarcenogenic, antifungal and antiparasitic properties of protein A could be a good